Select your country or region
  • Africa
  • America
  • Asia
  • Europe
  • Oceania
Select your country / region
  • Angola
  • Cape Verde
  • Egypt
  • Guinea-Bissau
  • Mozambique
  • São Tomé and Príncipe
Select your country / region
  • Australia
  • New Zealand
Select your country / region
  • Bahrain
  • Bangladesh
  • Brunei
  • Cambodia
  • China
  • Dubai (United Arab Emirates)
  • Hong Kong SAR
  • India
  • Indonesia
  • Iraq
  • Japan
  • Jordan
  • Kuwait
  • Laos
  • Lebanon
  • Malaysia
  • Oman
  • Pakistan
  • Philippines
  • Qatar
  • Saudi Arabia
  • Singapore (Asia Pacific)
  • South Korea
  • Sri Lanka
  • Taiwan, China
  • Thailand
  • Vietnam
  • Yemen
  • Andorra
  • Austria
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Gibraltar
  • Iceland
  • Ireland
  • Italy
  • Norway
  • Poland
  • Portugal
  • San Marino
  • Slovak Republic
  • Spain
  • Spain (Headquarters)
  • Sweden
  • Switzerland
  • United Kingdom
  • Vaticano
Select your country / region
  • Argentina
  • Aruba
  • Bolivia
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Costa Rica
  • Curacao
  • Dominican Republic
  • Ecuador
  • El Salvador
  • Guatemala
  • Honduras
  • Mexico
  • Nicaragua
  • Panama
  • Paraguay
  • Peru
  • Surinam
  • Trinidad and Tobago
  • United States
  • Uruguay
  • Venezuela

Grifols Deutschland GmbH

Grifols Deutschland was established in 1997. Based in Frankfurt, we manage the Biopharma sales in Germany, and Diagnostic sales in the German, Austrian and Swiss (DACH) markets.

We offer a comprehensive portfolio of Grifols products and services. Safety and quality are our top priorities as we deliver on our mission to improve the health and well-being of people around the world.

Grifols Deutschland

Colmarer Strasse 22
60528 Frankfurt am Main

Contact information
Tel: +49 (69) 660593100
Fax: +49 (69) 660593110


Notification of adverse reactions
To report an adverse drug reaction click here

Contact with Grifols

Type of consultation *
  • Adverse event
  • Customer Service
  • Other
  • Product Inquiry
  • Product technical complaint
  • Sales Visit
  • Technical Support

By clicking the button below, I declare being informed that my data is being used as described in the data protection information.

Data controller The Grifols’ group company to which you submit the request.
Purpose To manage your requests of information, suggestions and/or queries.
Legal basis Legitimate interest.
Recipients · Grifols’ group companies
· Other third parties
Rights To access, rectify and erase personal data, as well as other rights detailed in the additional information section.
Additional information For additional information on personal data protection check here.


Industry interactions with the medical profession have a profound and positive influence on patient treatment and on the value of research. As primary providers of healthcare services, both healthcare professionals and healthcare organizations offer us unique, independent insights and expert knowledge on patients' behavior and management of diseases. The ability to gain access to this expertise plays a critical role in informing and guiding industry efforts to improve the quality of patient care and treatment options. And this is why both healthcare professionals and healthcare organizations should be fairly compensated for their contributions, as well as for the services they provide to the industry.

Industry interactions with healthcare professionals and healthcare organizations should not only be conducted with integrity, but also should be transparent. And this is why Grifols Group fully supports, and has voluntarily adopted, the practices reflected in the new EFPIA Code of Practice and will continue to support any other country codes that promulgate transparency reporting.

In this regard, Grifols Deutschland supports transparent documentation of all collaborations with healthcare professionals and organizations and aligns its internal transparency guidelines with those of the EFPIA Code of Practice, FSA (Freiwillige Selbstkontrolle für die Arzneimittelindustrie e. V.) Code and AKG (Arzneimittel und Kooperation im Gesundheitswesen e.V.) Code of Conduct. Based on these guidelines, Grifols Deutschland publishes, within a publicly available list, all its interactions with German-based healthcare professionals and healthcare organizations.

As of 2021 reporting exercise, these interactions are published using the EFPIA disclosure template, which are grouped and split into four categories: (a) Research and Development; (b) Donations; (c) Sponsoring of Educational Events; and (d) Honoraria for Services. Interactions within the category "Research and Development" are published in an aggregate format. In the other categories, interactions are to be published in an individual format, in so far as permitted under German legal requirements on personal data protection.Transparency Germany 2021.

Commitment to patients

Every day at Grifols, patients inspire our mission to advance the discovery and development of plasma-derived medicines and other innovative biopharmaceutical therapies that improve health and well-being. To further our mission, Grifols Deutschland GmbH actively supports patient organizations, programs and services that promote education, disease awareness and patient advocacy efforts to improve the diagnosis and treatment of disease.